“Our biosimilars decision maintains high quality of care while providing flexibility and choice for patients and providers, with no disruption to treatment.” “The availability of Humira biosimilars is one of the biggest opportunities in years to lower costs and increase accessibility for consumers who need expensive specialty drugs,” OptumRx said in a statement Tuesday.